Danese S, Panaccione R, Feagan BG, Afzali A, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol 2023 Dec 14:S2468-1253(23)00318.
PMID: 38104569